Curon Biophama, a Shanghai immuno-oncology startup, announced a $150 million Series A financing. 6 Dimensions Capital incubated the company and participated in the fundraising, which was joined by Boyu Capital and Temasek. Curon already has several “promising” novel cancer I-O agents in its pipeline, according to the company. It plans to use the proceeds of the funding to advance its pipeline products into pre-clinical and clinical development, while it expands its portfolio, presumably through in-licensing.
Source: China Biotoday
